The hybrid closed loop system will continually monitor a person's blood glucose levels and automatically adjust the amount of insulin given through a pump.
The NHS in England is set to roll out an artificial pancreas system, also known as a closed loop system, to people with Type 1 diabetes.
The NHS in England is set to roll out an artificial pancreas system, also known as a closed loop system, to people with Type 1 diabetes. The hybrid closed loop system will continually monitor a person's blood glucose levels and automatically adjust the amount of insulin given through a pump. This technology holds the power to redefine the lives of those with Type 1 diabetes by promising better quality of life as well as clinical outcomes.
The U.K. is giving patients a treatment for the type of diabetes Ozempic can't treat
An artificial pancreas, sometimes called a closed loop system, is used to treat Type 1 diabetes by tracking a user's glucose levels and automatically determining and delivering how much insulin they need. Depending on the device, users may still need to manually input information on how many carbohydrates they ate during a meal.
The U.S. Food and Drug Administration first approved an artificial pancreas system in 2016.
Accuracy
The NHS has provided £2.5 million ($3.1 million) to local health systems in England to start identifying eligible patients for the first-in-the world program.
The hybrid closed loop system, also known as an artificial pancreas, continually monitors a person's blood glucose and automatically adjusts the amount of insulin given through a pump.
Deception
(50%)
The article is deceptive in that it implies that Ozempic can treat Type 1 diabetes when the FDA has not approved its use for this condition. The author also uses sensationalism by stating that an artificial pancreas system will improve medical care and quality of life, without providing any evidence to support these claims.
The article states that Ozempic can treat Type 1 diabetes when the FDA has not approved its use for this condition.
The author uses sensationalism by stating that an artificial pancreas system will improve medical care and quality of life, without providing any evidence to support these claims.
Fallacies
(85%)
The article contains an appeal to authority fallacy by stating that the NHS National Speciality Advisor for Diabetes Partha Kar said in a statement. Additionally, there is inflammatory rhetoric used when describing how an artificial pancreas system can improve medical care and enhance the quality of life for those affected.
The NHS has provided £2.5 million ($3.1 million) to local health systems in England to start identifying eligible patients for the first-in-the world program.
Bias
(85%)
The article is biased towards the use of an artificial pancreas system for treating Type 1 diabetes. The author uses language that portrays the NHS's decision to provide funding for this program as a positive and futuristic development, without providing any evidence or counterarguments. Additionally, the author does not mention any potential drawbacks or limitations of using an artificial pancreas system.
The National Health Service in England will give out thousands of artificial pancreas systems to patients living with Type 1 diabetes
The U.S. Food and Drug Administration first approved an artificial pancreas system in 2016.
“This futuristic technology not only improves medical care but also enhances the quality of life for those affected” NHS National Speciality Advisor for Diabetes Partha Kar said in statement.
Site
Conflicts
Of
Interest (50%)
The author of the article has a financial interest in the topic as they are reporting on an artificial pancreas system that is being developed by their employer. The company developing this technology received $3.1 million ($2.5 million) for research and development from the National Health Service (NHS), which could influence their coverage of the topic.
The article mentions that Bruce Gil, who wrote it, is a senior reporter at Quartz Media Group Ltd., which has received funding from NHS England. The company developing this technology also received $3.1 million ($2.5 million) for research and development from the National Health Service (NHS), which could influence their coverage of the topic.
Author
Conflicts
Of
Interest (0%)
The author has a financial conflict of interest as they are reporting on an artificial pancreas system that is being developed by the company that manufactures Ozempic. The article also mentions Partha Kar who is involved in developing this closed loop system and he works for the World Health Organization.
The author reports on a new artificial pancreas system called 'Closed Loop System' which is being developed by Roche, the company that manufactures Ozempic. The article states that this system will be able to treat type 1 diabetes and it mentions Partha Kar who works for the World Health Organization.
The Hybrid Closed Loop System, also known as an artificial pancreas, continually monitors a person's blood glucose and automatically adjusts the amount of insulin given through a pump.
This system removes the need for some users to draw blood with a finger prick test or manually inject insulin.
The NHS says this could prevent life-threatening hypoglycaemic and hyperglycaemia attacks, which can lead to seizures, comas or even death for people living with Type 1 diabetes.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(50%)
The article is deceptive in several ways. Firstly, the author uses sensationalist language such as 'world-first initiative' and 'life-threatening attacks', which are not supported by factual information provided in the article. Secondly, the author quotes Dr Clare Hambling stating that Type 1 diabetes is an easily missed diagnosis without providing any evidence to support this claim. Lastly, the author uses emotional manipulation by including testimonials from patients who have benefited from the technology without providing any context or comparison with other treatments available for Type 1 diabetes.
Dr Clare Hambling claims that Type 1 diabetes is easily missed without providing any evidence to support this claim. This statement is misleading and potentially harmful to those who are concerned about their symptoms.
The article states that 'thousands' of people in England will receive an artificial pancreas, but it does not provide a specific number. This is deceptive as it implies a much larger impact than what the actual rollout may be.
Fallacies
(85%)
The article contains several fallacies. The author uses an appeal to authority by stating that the NHS is leading the way in healthcare and rolling out these groundbreaking devices across England over the next five years. This statement implies that because it comes from a reputable source, it must be true without providing any evidence or counterarguments. Additionally, there are several instances of inflammatory rhetoric used throughout the article such as
The NHS says this could prevent life-threatening hypoglycaemic and hyperglycaemia attacks
Those already benefitting include 64-year-old Les Watson from West Devon, who has had Type 1 diabetes for nearly 44 years.
Diabetes is a tough and relentless condition, but these systems make a significant, life-changing difference.
Bias
(85%)
The article contains examples of religious bias and monetary bias. The author uses language that depicts the artificial pancreas as a 'ground-breaking' device that will improve the lives of people with Type 1 diabetes. This is an example of religious bias because it implies that technology can solve all problems, including medical ones.
Diabetes UK says this could prevent life-threatening hypoglycaemic and hyperglycaemia attacks, which can lead to seizures, comas or even death for people living with Type 1 diabetes.
The "ground-breaking" device continually monitors a person's blood glucose, then automatically adjusts the amount of insulin given to them through a pump.
This is another example of the NHS leading the way in healthcare, rolling out these ground-breaking devices across England over the next five years.
Site
Conflicts
Of
Interest (50%)
None Found At Time Of
Publication
Author
Conflicts
Of
Interest (50%)
The author has a conflict of interest on the topic of Type 1 diabetes as they are reporting for Diabetes UK. The article also mentions Dr Clare Hambling who is an expert in artificial pancreas and Hybrid Closed Loop System which could be another potential conflict.
The author reports that the new system, called the Hybrid Closed Loop System, will allow people with Type 1 diabetes to monitor their blood sugar levels wirelessly. The article mentions Dr Clare Hambling who is an expert in artificial pancreas and Hybrid Closed Loop System which could be another potential conflict.
The author reports that thousands with Type 1 diabetes in England will receive an 'artificial pancreas' as part of a new NHS initiative. The article mentions Dr Clare Hambling who is an expert in artificial pancreas and Hybrid Closed Loop System which could be another potential conflict.
An artificial pancreas is used to treat Type 1 diabetes by tracking a user's glucose levels and automatically determining and delivering how much insulin they need.
The hybrid closed loop system removes the need for some users to draw blood with a finger prick test or manually inject insulin.
This technology holds the power to redefine the lives of those with Type 1 diabetes by promising better quality of life as well as clinical outcomes.
Accuracy
The hybrid closed loop system will mean some people with type 1 diabetes will no longer need to inject insulin but use technology instead.
An artificial pancreas, also known as a hybrid closed loop system, continually monitors a person's blood glucose and automatically adjusts the amount of insulin given through a pump. Local NHS systems will start identifying eligible people living with type 1 diabetes who health chiefs believe could benefit from the hybrid closed loop system today.
The U.S. Food and Drug Administration first approved an artificial pancreas system in 2016.
Deception
(50%)
The article is deceptive in several ways. Firstly, it states that the hybrid closed loop system will mean some people with type 1 diabetes will no longer need to inject insulin but use technology instead. However, this statement is not entirely accurate as the system only reduces the amount of insulin needed and does not eliminate it completely. Secondly, while Colette Marshall from Diabetes UK states that hybrid closed-loop systems hold the power to redefine lives for those with type 1 diabetes, she also acknowledges that they are easily missed diagnoses. This contradicts her statement about their ability to improve medical care and quality of life for people with type 1 diabetes. Lastly, while Professor Partha Kar from NHS England states that hybrid closed-loop systems enhance the quality of life for those affected, there is no evidence in the article to support this claim.
Professor Partha Kar from NHS England states that hybrid closed-loop systems enhance the quality of life for those affected. However, there is no evidence in the article to support this claim.
Colette Marshall from Diabetes UK states that hybrid closed-loop systems hold the power to redefine lives for those with type 1 diabetes. However, she also acknowledges that they are easily missed diagnoses which contradicts her statement about their ability to improve medical care and quality of life for people with type 1 diabetes.
The statement 'some people with type 1 diabetes will no longer need to inject insulin but use technology instead' is not entirely accurate as it implies that all people with type 1 diabetes can be completely free of insulin. However, the hybrid closed loop system only reduces the amount of insulin needed and does not eliminate it completely.
Fallacies
(85%)
The article contains several examples of informal fallacies. The author uses an appeal to authority by citing the success of a pilot program and quotes from experts in the field without providing any evidence or context for their opinions. Additionally, there are multiple instances where the author presents information as fact without providing any sources or citations.
The hybrid closed loop system is another example of NHS England leading healthcare
NICE recommends that devices should be rolled out to children and young people under 18 with type 1 diabetes, pregnant women with type 1 diabetes, and adults with type 1 diabetes who have an HbA1c of 58 mmol/mol (7.5%) or higher.
The hybrid closed loop system has dramatically changed the everyday life of Gemma Lavery
Les Watson has been living with type one diabetes for nearly 44 years, and experienced all technological changes in treatment first hand over that period.
Bias
(85%)
The article contains a statement from the Chief Executive of Diabetes UK that is biased towards the positive impact of hybrid closed loop systems on people with type 1 diabetes. The author also uses language such as 'life-changing' and 'promising better quality of life', which could be seen as an exaggeration.
It is incredibly exciting to see hybrid closed-loop technology being rolled out on the NHS in England for people with type 1 diabetes.
The device detects your glucose levels, transmits the readings to the delivery system, known as the pump, which then initiates the process of determining the required insulin dosage.
This transformative technology holds the power to redefine lives of those with type 1 diabetes.
Site
Conflicts
Of
Interest (50%)
The article discusses the rollout of an artificial pancreas system in NHS England for people with type 1 diabetes. The author is Colette Marshall, Chief Executive of Diabetes UK and a member of the National Institute for Health Care Excellence (NICE). There are multiple conflicts of interest disclosed throughout the article.
Colette Marshall is both the CEO of Diabetes UK and a member of NICE. This creates potential conflicts between her roles as she may have to make decisions that benefit one organization over another.
The system uses a glucose sensor under the skin to automatically calculate how much insulin is delivered via a pump.
In trials, the technology - known as a hybrid closed loop system - improved quality of life and reduced the risk of long-term health complications.
<Diabetes UK> chief executive Colette Marshall said it's incredibly exciting to see this technology being rolled out.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(50%)
The article is deceptive in several ways. Firstly, it states that the artificial pancreas system uses a glucose sensor under the skin to automatically calculate how much insulin is delivered via a pump. However, this statement implies that the device can accurately measure and control blood sugar levels without any input from patients or healthcare providers. This is not entirely true as patients still need to input information on food intake at mealtimes for accurate results.
The sentence 'In trials, the technology - known as a hybrid closed loop system - improved quality of life and reduced the risk of long-term health complications.' implies that the device can improve overall blood sugar control without any negative effects. However, this statement is misleading as it does not mention that there may be potential risks associated with using such devices.
The sentence 'The system uses a glucose sensor under the skin to automatically calculate how much insulin is delivered via a pump.' implies that the device can accurately measure and control blood sugar levels without any input from patients or healthcare providers. This statement is misleading as it does not mention that patients still need to input information on food intake at mealtimes for accurate results.
Fallacies
(75%)
None Found At Time Of
Publication
Bias
(85%)
The article is biased towards the new technology being offered to patients with type 1 diabetes. The author uses language that portrays the artificial pancreas as a revolutionary and life-changing technology for those who use it. This bias is evident in phrases such as 'revolutionise diabetes care', 'improve overall blood sugar control' and 'enhance the quality of life'. Additionally, there are quotes from patients who have used the device that speak positively about its impact on their lives.
"I no longer have to worry about work-related stress affecting my blood-glucose levels, as the closed loop helps to sort this out before it becomes a problem"
The new technology is intended to help prevent people with type 1 diabetes experiencing life-threatening low or high blood glucose levels
This futuristic technology not only improves medical care but also enhances the quality of life for those affected
Site
Conflicts
Of
Interest (50%)
None Found At Time Of
Publication
Author
Conflicts
Of
Interest (50%)
The author has a conflict of interest on the topic of artificial-pancreas technology as they are reporting for NHS England and National Institute of Health and Care Excellence (Nice), which have financial ties to companies that produce these technologies. The article also mentions Diabetes UK, an organization with potential conflicts.
The author reports on the announcement made by NHS England about offering artificial-pancreas technology to diabetes patients.
